Literature DB >> 1711414

Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin.

T Sethi1, E Rozengurt.   

Abstract

We tested whether Ca(2+)-mobilizing neuropeptides can function as growth factors for small cell lung carcinoma cells. The neuropeptides bradykinin, neurotensin, cholecystokinin, and vasopressin at nanomolar concentrations stimulated a rapid and transient increase in the intracellular concentration of Ca2+. Crucially, these peptides in the same concentration range also caused a marked increase in colony formation in semisolid medium in responsive small cell lung carcinoma cell lines. At optimal concentrations bradykinin, neurotensin, cholecystokinin, vasopressin, galanin, and gastrin-releasing peptide were equally effective in promoting clonal growth. These findings support the hypothesis that small cell lung carcinoma growth is sustained by an extensive network of autocrine and paracrine interactions involving multiple neuropeptides.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711414

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  New perspectives in lung cancer. 2. Growth factors and lung cancer.

Authors:  P J Woll
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

2.  Rap1 mediates galanin receptor 2-induced proliferation and survival in squamous cell carcinoma.

Authors:  Rajat Banerjee; Bradley S Henson; Nickole Russo; Alex Tsodikov; Nisha J D'Silva
Journal:  Cell Signal       Date:  2011-02-21       Impact factor: 4.315

3.  E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer.

Authors:  J M Coulson; C E Fiskerstrand; P J Woll; J P Quinn
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

4.  Growth factors, antagonists and lung cancer.

Authors:  P J Woll
Journal:  J R Soc Med       Date:  1993-11       Impact factor: 5.344

5.  In various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist.

Authors:  S Drube; C Liebmann
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

6.  G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of Galpha(q) and Galpha(i) signals.

Authors:  A Blaukat; A Barac; M J Cross; S Offermanns; I Dikic
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

7.  Bradykinin binding sites in healthy and carcinomatous human lung.

Authors:  A Trifilieff; E Lach; P Dumont; J P Gies
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

8.  CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Paola Moreno; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2015-03-12       Impact factor: 3.444

Review 9.  Cancer stem cells in small cell lung cancer.

Authors:  Jordi Codony-Servat; Alberto Verlicchi; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 10.  Neurohypophyseal peptides as regulators of growth and development. A review.

Authors:  D A Carter; C K Fai; D Murphy
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.